miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to complementary target regions on gene transcripts. Thus, miRNAs fine-tune gene expression profiles in a cell-type-specific manner and thereby regulate important cellular functions, such as cell growth, proliferat...

Full description

Bibliographic Details
Main Authors:	Florian Huemer, Michael Leisch, Roland Geisberger, Nadja Zaborsky, Richard Greil
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	Pharmaceuticals
Subjects:	miRNA microRNA immune-checkpoint inhibitor immune-checkpoint blockade predictive ipilimumab
Online Access:	https://www.mdpi.com/1424-8247/14/2/89

id	doaj-2ef30622844e46da87665906abebda6e
record_format	Article
spelling	doaj-2ef30622844e46da87665906abebda6e2021-01-27T00:02:16ZengMDPI AGPharmaceuticals1424-82472021-01-0114898910.3390/ph14020089miRNA-Based Therapeutics in the Era of Immune-Checkpoint InhibitorsFlorian Huemer0Michael Leisch1Roland Geisberger2Nadja Zaborsky3Richard Greil4Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, AustriaMicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to complementary target regions on gene transcripts. Thus, miRNAs fine-tune gene expression profiles in a cell-type-specific manner and thereby regulate important cellular functions, such as cell growth, proliferation and cell death. MiRNAs are frequently dysregulated in cancer cells by several mechanisms, which significantly affect the course of the disease. In this review, we summarize the current knowledge on how dysregulated miRNAs contribute to cancer and how miRNAs can be exploited as predictive factors and therapeutic targets, particularly in regard to immune-checkpoint inhibitor therapies.https://www.mdpi.com/1424-8247/14/2/89miRNAmicroRNAimmune-checkpoint inhibitorimmune-checkpoint blockadepredictiveipilimumab
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Florian Huemer Michael Leisch Roland Geisberger Nadja Zaborsky Richard Greil
spellingShingle	Florian Huemer Michael Leisch Roland Geisberger Nadja Zaborsky Richard Greil miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors Pharmaceuticals miRNA microRNA immune-checkpoint inhibitor immune-checkpoint blockade predictive ipilimumab
author_facet	Florian Huemer Michael Leisch Roland Geisberger Nadja Zaborsky Richard Greil
author_sort	Florian Huemer
title	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
title_short	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
title_full	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
title_fullStr	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
title_full_unstemmed	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
title_sort	mirna-based therapeutics in the era of immune-checkpoint inhibitors
publisher	MDPI AG
series	Pharmaceuticals
issn	1424-8247
publishDate	2021-01-01
description	MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to complementary target regions on gene transcripts. Thus, miRNAs fine-tune gene expression profiles in a cell-type-specific manner and thereby regulate important cellular functions, such as cell growth, proliferation and cell death. MiRNAs are frequently dysregulated in cancer cells by several mechanisms, which significantly affect the course of the disease. In this review, we summarize the current knowledge on how dysregulated miRNAs contribute to cancer and how miRNAs can be exploited as predictive factors and therapeutic targets, particularly in regard to immune-checkpoint inhibitor therapies.
topic	miRNA microRNA immune-checkpoint inhibitor immune-checkpoint blockade predictive ipilimumab
url	https://www.mdpi.com/1424-8247/14/2/89
work_keys_str_mv	AT florianhuemer mirnabasedtherapeuticsintheeraofimmunecheckpointinhibitors AT michaelleisch mirnabasedtherapeuticsintheeraofimmunecheckpointinhibitors AT rolandgeisberger mirnabasedtherapeuticsintheeraofimmunecheckpointinhibitors AT nadjazaborsky mirnabasedtherapeuticsintheeraofimmunecheckpointinhibitors AT richardgreil mirnabasedtherapeuticsintheeraofimmunecheckpointinhibitors
_version_	1724322140311781376

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors

Similar Items